Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Mease PJ, et al. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi: 10.1002/art.21306. Arthritis Rheum. 2005. PMID: 16200601 Free article. Clinical Trial.
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD. Mease PJ, et al. Among authors: perdok rj. Ann Rheum Dis. 2009 May;68(5):702-9. doi: 10.1136/ard.2008.092767. Epub 2008 Aug 6. Ann Rheum Dis. 2009. PMID: 18684743 Free PMC article. Clinical Trial.
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Gladman DD, et al. Among authors: perdok rj. Ann Rheum Dis. 2007 Feb;66(2):163-8. doi: 10.1136/ard.2006.057901. Epub 2006 Oct 17. Ann Rheum Dis. 2007. PMID: 17046964 Free PMC article. Clinical Trial.
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J; ABT-874 Study Investigators. Kimball AB, et al. Among authors: perdok rj. J Am Acad Dermatol. 2011 Feb;64(2):263-74. doi: 10.1016/j.jaad.2010.01.030. Epub 2010 Dec 9. J Am Acad Dermatol. 2011. PMID: 21145618 Clinical Trial.
Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia.
Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM. Lynch DR, et al. Among authors: perdok r. Ann Clin Transl Neurol. 2019 Feb 27;6(3):546-553. doi: 10.1002/acn3.731. eCollection 2019 Mar. Ann Clin Transl Neurol. 2019. PMID: 30911578 Free PMC article. Clinical Trial.
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. Among authors: perdok r. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
12 results